drugset

drugset / Trial / NCT02950467

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467 ↗

Phase 1 Completed 30 enrolled Joshua Woolley Heffter Research Institute · collab RiverStyx Foundation · collab Stupski Foundation · collab Usona Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

Timeline

Start: 2018-01-05
Primary completion: 2019-12-31
Completion: 2019-12-31

Publications

Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Sep 24;27:100538. doi: 10.1016/j.eclinm.2020.100538. eCollection 2020 Oct.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	0.3 mg/kg	Oral
Subject	Psilocybin	Other / unclassified	0.36 mg/kg	Oral

Indications